Co-Amoxiclav powder for oral suspension 250/62.5 mg/mL
Published: 5 November 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) has published a class 4 medicines defect notification. Sandoz Limited has informed the MHRA of errors in the dosing table in the Summary of Product Characteristics (SmPC) for co-amoxiclav 250/62.5 mg/5 ml powder for oral suspension. The quality of the powder for oral suspension is not impacted by this defect.
The dosing table in Section 4.2 of the defective SmPC, that provides the instruction for weight adjusted dosing, is incorrect and should not be used. The defective SmPC has been removed from the MHRA products and electronic medicines compendium (eMC) websites.
The defective SmPC dosing table instructed an amount of oral suspension that provided approximately twice the intended recommended dose.
Further information, advice and details of the affected batches can be found on the MHRA website.